Aneuvo Raises $22M in Series C Funding to Scale Neuromodulation Therapy

For spinal cord injury, progress is measured in inches. Aneuvo is trying to turn inches into something repeatable. The Los Angeles-based neurotech company secured $22M in Series C funding led by Catcher Technology Co., Ltd., a move aimed squarely at strengthening regulatory readiness and scaling global operations around ExaStim. Not noise. Momentum. The kind that starts showing up in clinics, conferences, and quiet conversations among people who know where medical innovation is heading next.

Credit where it is due. Congratulations to Co Founder and CEO Yi-Kai Lo and Co Founder Professor Wentai Liu for pushing a vision that has lived at the intersection of engineering nerve and clinical patience since 2016. Building serious medical technology is not a sprint through a pitch deck. It is years of research, regulatory chess, and proving the science when nobody is handing out applause. ExaStim is the result of that grind. A non invasive neuromodulation system designed to help restore motor function for people living with chronic spinal cord injury. Electricity delivered with surgical precision, but without the surgery.

The technology itself is the part that makes engineers lean forward. ExaStim sends targeted stimulation through a multi electrode pad placed along the spine, activating nerves and circuits that spinal injuries often silence. The system runs through proprietary software on a mobile digital device, which means clinicians can program therapy that fits real rehabilitation workflows instead of forcing therapy to fit the machine. That practicality matters. Hospitals do not buy science projects. They buy tools that fit into the rhythm of care.

This round arrives at a moment when the company already has serious traction. ExaStim holds CE Mark certification in Europe and carries FDA Breakthrough Device Designation in the United States. Clinical work through the nationwide ASPIRE trial continues building the evidence base that regulators and clinicians demand before new therapies become standard practice. Translation. The science is moving through the gates that matter, one checkpoint at a time.

The $22M infusion now gives ANEUVO room to do what scaling medtech companies must do next. Strengthen manufacturing, deepen regulatory work, expand commercial operations, and prepare the infrastructure that turns breakthrough devices into real world therapies. Catcher Technology Co., Ltd. stepping in as lead investor signals something else too. Hardware expertise meeting bioelectronic medicine is not a coincidence. It is a strategic alignment that could accelerate how quickly ExaStim reaches the patients and rehabilitation centers that have been waiting for something exactly like this. And in a field where progress is usually measured in inches, even a small surge forward can feel like the entire industry just leaned into the future a little harder.